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With antiobesity agents, weight loss can emerge from an array of metabolic, cognitive and behavioural
changes that translate into weight change over time. In early drug development, characterising these
changes can actually be more informative than simply measuring weight loss. Biomarkers for these
mechanisms can be used to determine whether potential compounds are worth developing further by
providing proof of mechanistic action and detecting early signs of neuropsychiatric adverse effects. In this
review, we examine potential biomarkers for effects on metabolism and satiety, hedonics and motivation,
and eating behaviour. We also review biomarkers for early detection of neuropsychiatric adverse effects.Introduction
During the past five years, several antiobesity agents have been
withdrawn at different stages in the drug development process
because of concerns about limited efficacy, safety or both. The
most notable have been rimonbant, withdrawn because of its
neuropsychiatric adverse effects (depression, suicidality) [1], and
sibutramine, because of its cardiovascular risks [2]. 2012 saw the
first FDA approvals for two antiobesity agents since orlistat in
1999. These were lorcaserin (selective serotonin 5-HT2C agonist)
[3] and Qysmia1 (the stimulant phentermine, which suppresses
appetite and increases metabolic rate, and the antiepileptic topir-
amate) [4]. However, neither was approved by the European
Medicines Agency (EMEA), which was not sufficiently satisfied
about the safety of either drug [5,6]. Contrave1 (noradrenaline
and dopamine re-uptake inhibitor buproprion and mu-opioid
antagonist naltrexone) received a positive recommendation from
the FDA advisory committee in late 2010 but was not approved
because of safety concerns [7,8]. It is currently in further Phase III
trials. Another combination EmpaticTM (buproprion and the anti-
epileptic zonisamide) has completed Phase IIb [9] and both theseCorresponding author:. Ziauddeen, H. (hz238@cam.ac.uk)
1282 www.drugdiscoverytoday.com 1359-6446/06 2013 The Auagents show promising early efficacy signals. However, over this
period several other agents have not progressed. The D3-antagonist
GSK588089 failed to demonstrate mechanistic efficacy in Phase I
[10,11]. The cannabinoid CB1 receptor inverse agonist taranabant
[12,13] and antagonist otenabant [14] showed similar adverse
effects to rimonabant. The development of metreleptin/pramli-
nitide (leptin analogue and synthetic amylin) was terminated
possibly following antibody reactions to metreleptin [15]. Agents
currently in Phase I and II include the mu-opioid receptor (MOR)
antagonist GSK1521498, the triple monoamine reuptake inhibi-
tor tesofensine [16,17], the glucagon-like peptide 1 (GLP-1) ana-
logue liraglutide [18], the neuropeptide Y (Y1 and Y5) agonist
velneperit, the neutral cannabinoid antagonists and the MC4R
receptor agonist RM493 [19].
This is not a comprehensive summary of the state of the field and
is only meant to highlight the challenges for, and the very modest
returns from, a large and costly antiobesity drug development
programme. The challenge is partly due to the licensing regulatory
requirement(s) of the FDA and the EMEA. Both require an agent to
demonstrate statistically significant weight loss (compared with
placebo) at one year in large Phase III trials [20,21]. The FDA also
requires combination treatments to demonstrate superiority over
each individual component before Phase III. An acceptable safety
profile is crucial and neuropsychiatric adverse effects and abuse
liability are particular concerns with centrally acting agents. Addi-
tionally, in 2012 the FDA advisory committee recommended that allthors. Published by Elsevier B.V. http://dx.doi.org/10.1016/Open access under CC BY license.
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less of theoretical risk or signal of cardiovascular harm) before
approval [22]. The journey to licensing for a new agent is, therefore,
necessarily a long and costly one.
In this review we consider whether biomarkers can be used to
provide early signals of efficacy and/or adverse effects in Phase I
and II to enable early go–no-go decisions and possibly have value
as surrogate endpoints. Our focus here is on neuroimaging and
neurobehavioural measures for centrally acting agents. There are
very few examples of this experimental medicine approach in
obesity with fewer replications and no real validation studies of
these biomarkers. Our aim therefore is to present some potential
candidates for development and validation. We also discuss their
limitations and, particularly, the question of what biomarkers add
to the body weight signal that is ultimately paramount for efficacy
and regulatory approval.
Some difficulties in antiobesity drug development
We would first briefly like to highlight three potential problems in
the field that have been elegantly discussed previously [23]. The
first is that the weight loss endpoint is some way downstream of
the target mechanism of a dug and can result from a combination
of different mechanisms acting simultaneously or successively.
Given the complex multiple pathways to positive energy balance
and consequent obesity [24], it seems unlikely that it would be
possible to target safely even a very proximal pathway such as
orexigenic drive in the hypothalamus to a sufficient extent to
produce significant and, crucially, sustained weight loss, without
addressing the processes distal to this. The second is that to focus
on weight loss is to focus on the ‘consequences rather than the
causes’ [23]. The mechanisms that led to the initial weight gain
need to be treated alongside or after weight loss treatment given
the high risk of weight regain. There could be considerable value in
drugs that facilitate weight maintenance by targeting these cau-
sative mechanisms, even if they do not achieve weight loss. A third
difficulty is the conceptualisation of obesity as a homogenous
syndrome that should respond predictably to an antiobesity treat-
ment. It is likely that common obesity is a very heterogeneous
syndrome, even without accounting for comorbidities (e.g. Type 2
diabetes). Although diet and lifestyle modification are invaluable
as general treatments and at the public health level, treating a
specific patient might require a more individualised approach. It
could also be the case that certain eating behaviours (e.g. binge
eating) and pharmacogenotypes (e.g. MOR OPRM1 gene A118G
polymorphism) [25] are more amenable to specific treatments.
This might not be gleaned from heterogenous Phase III trial
populations that have not been stratified a priori to permit the
necessary subgroup analyses and makes a case for defining a target
subgroup in Phase II, based on the predicted mechanism of action
of the agent. This does however present theoretical and practical
challenges in terms of defining and recruiting the relevant
subgroup.
For the purposes of this article, we take the view of obesity as a
heterogenous syndrome with a multifactorial causation requiring
a multipronged and individualised treatment, of which pharma-
cology would be one prong. From this perspective we would argue
that the first requirement for a potential antiobesity agent is that it
should reliably and safely affect a specific target mechanism orbehaviour and it is here that we think that biomarkers could be
very valuable.
The value of biomarkers in early drug development
In drug development, a biomarker is a characteristic that is objec-
tively measured and evaluated as an indicator of pharmacological
response to a treatment. They can be used to monitor or predict
treatment response and can even serve as surrogate endpoints [26].
What would be the value of biomarkers in antiobesity drug
development? First, they could offer clear evidence of mechanistic
efficacy and could permit the detection of signals that would not
be immediately available (e.g. shifting food preference and desire,
subtle changes in mood) or be less easily accessible from subjective
report (e.g. attention bias to food or altered emotional processing).
Second, they can aid dose optimisation and the examination of
synergistic effects of combination treatments. Third, if a drug has a
proven mechanistic effect yet fails to cause sufficient weight loss
after optimal dosing it would suggest that modulating that
mechanism alone is insufficient for weight loss. Fourth, they could
aid in the early identification of adverse effects. Fifth, they could
also enable identification of target subgroups. These particular uses
would help decisions about proceeding with development and
optimising the process. Finally, a biomarker that predicts efficacy
would be an invaluable surrogate endpoint in the drug develop-
ment process. We will now examine some potential biomarkers
and their applications, present and potential (Table 1).
Biomarkers for mechanisms
Functional neuroimaging
At present, functional magnetic resonance imaging (fMRI), in the
context of a relevant cognitive task or state, remains the best
option for examining the neural effects of a drug. A useful fMRI
task for evaluating antiobesity drugs is viewing pictures of foods. It
is associated with robust neural responses (enhanced blood flow)
in key areas of the reward circuit (e.g. ventral striatum, orbito-
frontal cortex and amygdala) and the homeostatic system (e.g.
hypothalamus) when viewing rewarding foods compared to less
rewarding foods, or foods compared to non-foods [27–30]. These
responses are enhanced by hunger and attenuated by satiety [31–
34]. A drug that decreases appetite would be predicted to attenuate
the expected enhancement produced by the fasted state and one
that enhances satiety to enhance the attenuation produced by the
sated state. In overweight subjects, sibutramine 15 mg/day for two
weeks attenuated the hypothalamic and amygdala responses to
rewarding foods compared with less rewarding foods, independent
of whether participants were fed or fasted [28] (Fig. 1a). This
suggests that sibutramine reciprocally increases the anorexigenic
drive from hypothalamic pro-opiomelanocortin (POMC) neurons
and decreases the orexigenic drive from Agouti-related protein
(AgRP) neurons [35], as would be predicted by its serotonergic
action. Further, the degree of hypothalamic suppression correlated
with ad libitum intake and weight loss during the study. However,
in a study in obese subjects using the same treatment regime but a
different analysis approach, sibutramine enhanced amygdala
activity when viewing rewarding foods compared with non-foods
[36]. This difference emphasises a particularly important point
with respect to the use of functional neuroimaging as a biomarker:
it produces measures that are highly stimulus- and context-specificwww.drugdiscoverytoday.com 1283
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TABLE 1
Potential biomarkers for antiobesity drug development
Examining mechanisms of action
Biomarker Mechanism Application with
antiobesity drugs
Potential future study candidates
Neuroimaging (fMRI)
Food pictures task
Examination of neural responses in reward
and appetite control regions:
ventral striatum, orbitofrontal cortex,
insula, amygdala, putamen, hypothalamus
Attenuation of appetitive
drive/enhanced satiety
Sibutramine (+) [23] RM403 (+), Lorcaserin (+)
Liraglutide (+), Velneperit (+),
Tesofensine
Attenuation of food related reward Rimonabant (+) [35] Neutral cannabinoid antagonists ()
Attenuation of food specific reward GSK1521498 (+) [32]
GSK598809 () [7]
Neutral cannabinoid antagonists ()
Cognitive and behavioural
Ad libitum food intake
Intake on buffet meals, or ad libitum
consumption on single meals with or
without universal eating monitor (UEM)
Attenuation of appetitive
drive/enhanced satiety
Sibutramine (+) [47,48]
GSK1521498 (+) [20]
All above
Attention bias to food pictures
Speeded reaction time when target occurs
in location closer to food cue
Attenuation of salience of food cues GSK1521498 (+) [45]
GSK598809 () [6]
Tesofensine
Motivation for food rewards: picture surfing task
Greater force exerted to view rewarding foods
Attenuation of motivation
for food rewards
GSK1521498 (+) [32] Tesofensine
Expected satiety and satiation
Estimated portion size that will stave off
hunger or induce sufficient fullness
Attenuation of appetitive
drive/enhanced satiety
Not used so far Requires testing
Drugs that enhance satiety/
decrease appetite
Implicit wanting
Speeded reaction time in forced choice
comparisons of different food types
Attenuation of motivation
for food rewards
Not used so far As above
Examining potential neuropsychiatric adverse effects
Biomarker Mechanism/
adverse effect
Application with
antiobesity drugs
Potential future
study candidates
Neuroimaging (fMRI)
Neural responses to emotional face
processing in amygdala: enhanced
amygdala responsiveness to fearful faces
Mood, anxiety GSK1521498 () unpublished data Neutral cannabinoid antagonists ()
Cognitive and behavioural
Emotional processing:
Decrease in positive bias for self-relevant
words on recall or recognition
Mood, anxiety Rimonabant (+) [55,56] Neutral cannabinoid antagonists ()
Emotional face processing
Enhanced recognition for fearful faces
Mood disturbance Rimonabant () [55,56] Neutral cannabinoid antagonists ()
Measures of cognitive speed:
For example power of attention score
Sedation GSK1521498 () [45] Empatic ()
Contrave ()
Measures of memory:
For example CANTAB
Memory disturbance Not used so far Empatic ()
Contrave ()
In the third column (+) indicates that an effect was seen and () indicates that no effect was seen. In the fourth column the symbols indicate the desired effect for future agents.
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measures are to be useful for studying other agents targeting
appetite or satiety (e.g. lorcaserin, velneperit, liraglutide and teso-
fensine) then it would be important to develop standardised and
comparable approaches across studies.
A drug that attenuates the reward value of food would be pre-
dicted to cause a corresponding attenuation of reward circuit activ-
ity. In obese subjects 4 weeks of treatment with MOR antagonist
GSK1521498 produced a specific attenuation in a region of the
putamen in response to viewing rewarding compared with less
rewarding food pictures [37] (Fig. 1b). Although the spatial resolu-
tion of fMRI does not permit us definitely to say so, this particular
region might be the ventral pallidum, the site of a ‘hedonic hotspot’1284 www.drugdiscoverytoday.com[38], rich in MORs, and a target region for an agent that modulates
the hedonics of food reward. Interestingly, subjective liking ratings
for the food images were unchanged. This task can also be adapted to
examine the specificity of effects to food by including a category of
rewarding non-foods as was done in this study and the drug effect
was found to be specific to food images only [37]. Given the animal
data supporting the role of D3-receptors in drug and food seeking
[39], GSK598809 was developed for the treatment of compulsive
overeating and obesity. However, single doses of GSK598808
175 mg in overweight binge eaters had no effect on this task
[11].fMRI can also be used to study the neural responses to food
consumption by delivering liquid rewards to the subject in the
scanner. In healthy normal-weight volunteers, rimonabant 20 mg
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FIGURE 1
Neuroimaging biomarkers. (a) Shows the attenuation of neural activation in the hypothalamus (coordinates 4, 2, 6) by sibutramine (P = 0.014, small volume and
Bonferroni corrected) on the left [28]. This attenuation was correlated with the reduction in weight in the 11 subjects who received placebo first in the crossover
(Spearman’s rho = 0.81, P = 0.03). The parameter estimates from this region shown on the right demonstrates the specific effect of sibutramine in response to
rewarding foods (high cal) independent of fed/fasted state. (b) Shows the attenuation of the response in the putamen (22, 17, 8) to rewarding foods produced by
GSK1521498 [P < 0.05, Family Wise error (FWE) corrected]. The parameter estimates on the right show that this effect is specific to food and is produced by an
attenuation of the response to rewarding foods (HF) and an enhanced response to less rewarding foods (LF) [37]. (c) Displays the attenuating effect of rimonabant on
the ventral striatal response (16, 18, 10) to the taste of chocolate in the mouth (P < 0.05, FWE corrected). Parameter estimates are shown on the right [68].
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taste of chocolate milk (Fig. 1c). Subjects reported no subjective
change in mood or liking for chocolate, but did report a decrease in
chocolate intake during the treatment period [40]. The study also
reported enhanced lateral orbitofrontal cortex (OFC) response to an
aversive liquid. Once again with a hedonic system modulator we see
a very early signal of a mechanistic effect. However, this study was
terminated prematurely by the withdrawal of rimonabant and no
further examination of these effects or their specificity to food have
been reported.
The food pictures and the liquid reward delivery tasks would
be useful for evaluating other agents targeting hedonic systems(e.g. the neutral and the peripherally restricted cannabinoid
antagonists) [41]. The neutral antagonists lack the inverse agonism
of rimonabant and taranabant, and are less likely to disrupt con-
stitutive endocannabinoid signalling, potentially posing less neu-
ropsychiatric risk [42]. However it would be important to examine
the specificity of their effects. The peripherally restricted antago-
nists are hypothesised to affect cannabinoid-mediated lipogenesis
and appetite signalling in the periphery [43,44]. Here the impor-
tant question is whether these agents produce the same effects
as their centrally acting counterparts (absence of a direct
central action does not exclude secondary effects of peripheral
antagonism on neural activation). Of course, positron emissionwww.drugdiscoverytoday.com 1285
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of central nervous system (CNS) penetration of the peripherally
restricted agents [45].
The food pictures task has also been demonstrated to be sensitive
to the effect of gut hormones. Administration of leptin in leptin-
deficient patients restores the normal hunger and satiety neural
responses [46]. Ghrelin increases responses to food images in the
amygdala, OFC and striatum [47]. There is also preliminary evidence
that Peptide YY (PYY) and GLP-1 attenuate activity in the amygdala,
OFC, caudate, accumbens and insula, when viewing high calorie
food pictures in the fasted state [48]. These findings are relevant to
the development of potential agents based on these gut hormones.
Before we conclude this section it is important to acknowledge
the tremendous variability in the findings in the fMRI literature
using this task [49]. This is partly related to the lack of standardisa-
tion of this task or the analysis strategy but there is also genuine
individual variability. This is a major limitation when it comes to
comparing studies and developing biomarkers. At least at present,
using fMRI measures meaningfully requires a pre-treatment baseline
scan followed by a treatment scan to examine changes from the
baseline.
Cognition and behaviour
Assays of cognition and behaviour offer ways of identifying subtle
changes, even those inaccessible to consciousness that could
herald a key therapeutic effect when subjective measures and overt
changes are not (yet) manifest.
Attention bias measures
These measures examine the tendency for attention to be drawn
more strongly to food stimuli. In this task a food-related picture
and a non-food picture appear side by side onscreen for either 500
or 2000 ms, and are then replaced by a dot probe that appears in
the position occupied by one of the pictures. The participant has to
press the response key corresponding to that position. Attention
bias is reflected in faster reaction times for probes replacing food
pictures compared with those replacing non-food pictures [50].
GSK1521498 attenuated the attention bias for food stimuli in
obese subjects [51] (Fig. 2). However, the D3-antagonist
GSK598809 did not affect attention bias to foods except in indi-
viduals with low levels of dietary restraint [10].
Food related motivation measures
These examine the extent to which an individual is willing to work
to attain a food. In a novel grip-force task, participants exerted
force on a force transducer to view pictures of food and other
rewards. Two pictures were presented at each trial, one clearly
visible in the foreground and the other at a very small size in the
background. Exerting force on the transducer made the fore-
ground picture recede into the background and vice versa. Moti-
vation was examined in terms of the force exerted to view different
images (e.g. the force exerted to see rewarding foods instead of less
rewarding foods). At baseline obese subjects exerted greater force
to see highly rewarding foods despite no difference in their sub-
jective liking for the foods. However, after 4 weeks on GSK1521498
this effect was no longer present and the liking ratings now
discriminated between rewarding and less rewarding foods as
would usually be expected [37] (Fig. 2). The force exerted for
non-food rewarding images was unchanged, demonstrating a food
specific drug effect. Both the above measures could have value in1286 www.drugdiscoverytoday.comexamining the effect of drugs that modulate appetite and satiety,
but further work is required to demonstrate their sensitivity to
changes in hunger and/or satiety.
Laboratory measures of intake and preference
Although monitoring of real world food consumption is difficult
and unreliable, being dependent on self report, laboratory measures
of taste perception and eating behaviour have all been shown to
have good reliability for detecting treatment effects. Taste percep-
tion measures examine hedonic responses to varying concentra-
tions of fat and sugar using different dairy composites [52]. As
predicted for an MOR antagonist, GSK1521498 significantly atte-
nuated the preference for high fat and high sugar solutions [25].
Measures of intake include buffet meals and ad libitum consump-
tion of single item meals (e.g. pasta with tomato sauce). The latter
can be combined with a universal eating monitor (UEM), which uses
rating measures for hunger and fullness and concealed scales in the
serving table to monitor intake, eating rate and meal microstruc-
ture. Buffet meals can additionally be used to examine effects on
specific food categories and food preference. In obese women
sibutramine decreased consumption by almost 16% on an ad libitum
meal following 7 days of treatment with either 10 mg or 15 mg per
day. Greater effects were seen with 15 mg and sibutramine also
enhanced within meal satiation [53]. Similar effects were seen with 2
weeks of sibutramine 15 mg (Fig. 2) but importantly, in this study all
subjects continued on sibutramine for a further 10 months. Subjects
who ate less at the 14 day point lost more weight at 10 months
(11.8  6.2 kg; mean  SD) compared with those who ate more
(6.9  2.7 kg) [54]. GSK1521498 reduced caloric intake on an ad
libitum buffet meal by nearly 400 calories, with a particular effect on
the intake of high fat desserts [25] (Fig. 2). These intake measures are
simple to administer and would provide valuable information for a
potential agent. It is important to emphasise that they can most
reliably determine consumption. Food preference is much harder to
determine reliably given the multiple factors that determine it, and
requires very careful matching of food items for type, nutritional
content and flavour across different categories and test sessions.
Other potential measures
Decisions about food portions are captured by a measure of
expected satiety in which subjects adjust the size of a potential
meal serving on a computer to an amount that they think will
stave off hunger for a specified duration [55]. Implicit wanting
captures food-related motivation in terms of an implicit speeded
reaction time when making forced choices between various food
pairs [56]. Both these measures are potentially interesting and
useful but have not been used so far in studies of dieting or weight
loss to allow further comment. When using biomarkers with
agents that target appetite and satiety, where measures are taken
in the fasted and sated states, it is important to use a standardised
satiation manipulation.
Biomarkers for safety
There has been little work carried out investigating biomarkers for
safety. However there are some potentially promising findings that
would merit further exploration.
Functional neuroimaging
Neuroimaging studies of emotion processing examine the neural
responses to viewing fearful, happy or neutral faces. In depression
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FIGURE 2
Behavioural biomarkers. (a) Effect of 14 days of sibutramine on intake in a placebo crossover design, sibutramine decreases intake, which recovers on placebo [54].
(b) Effect of 28 days of GSK1521498 on intake on an ad libitum buffet. The second graph shows a significant effect on high fat desserts (*P < 0.05) [25]. (c) Effect of
28 days of GSK1521498 on grip-force exerted to view high fat food images (HF) compared to low fat images (LF). Greater effort is exerted to view HF images at
baseline but this attenuated in the treatment group but persists in the treatment group. Liking ratings also discriminate between HF and LF images in the
treatment group alone [37]. (d) GSK1521498 5 mg/day for 28 days reduces the attentional bias for food [51].
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This finding improves with even single doses of antidepressants
and could serve as a useful biomarker for mood effects [57,58].
GSK1521498 produced no effects on this task (unpublished data).
This measure has not been used with rimonabant, and would be
important for the newer cannabinoid antagonists and tesofensine,
given recent concerns [17] about underreporting of adverse effects
(including stress and depression) in the original tesofensine study
[16].
Cognition and behaviour
Emotional processing
Depression is associated with abnormalities of emotional proces-
sing including negative bias in the interpretation of ambiguous
information, decreased recognition of positive facial emotions and
impaired recall of positive self-referent words [59]. These effects
have been shown to be manifest early, even before mood is notably
depressed and they are improved by single doses of antidepressant
treatment [59,60]. In healthy volunteers a single dose of rimon-
bant 20 mg impaired the recall of positive self-referent words [61],
and 7 days of treatment impaired the recognition of previously
seen positive words [40] (Fig. 3). In both studies no effects were
seen on subjective mood. However, it should be noted that in both
studies no effect was seen on facial emotion recognition or other
related measures. These findings, although interesting, are none-
theless preliminary and require further exploration.
Cognition and sedation
The key point here is the clear need for the use of the standardised
cognitive tests for cognition and sedation instead of subjective
reports and rating scales. For example, using the power of atten-
tion score, which has been shown to be sensitive to drug-induced
sedation [62], GSK1521498 was found to have mild sedative effects
in Phase I [63]. However, these were found to be mild and transientM
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FIGURE 3
Effect of rimonabant on emotional processing. (a) Single dose of rimonabant attenu
(b) Seven days of treatment with rimonabant attenuates the recognition of posit
previously encountered words [40]. No effects are seen on negative or non-self-r
1288 www.drugdiscoverytoday.comin Phase II [51]. Rigorous cognitive measures would be important
for agents such as zonisamide and topiramate that have documen-
ted deleterious effects on memory and cognition. With agents that
can have nonspecific effects on reward processing, the specificity
of effects can be examined as discussed in the previous section.
Finally, although not strictly biomarkers, validated questionnaires
and scales for mood, anxiety and suicidality are easily adminis-
tered and provide important clinically relevant information.
How would these biomarkers be used in early drug
development?
We propose that such biomarkers could be useful in Phase I and II
of the drug development process. Simple measures of cognition
and tasks such as attention bias can be performed in Phase I
alongside safety and dosing assessments. However, it is in Phase
II that well designed proof-of-concept studies using such measures
could help provide robust signals of proof-of-mechanism or early
safety signals. As shown in the previous section, these measures
pick up drug effects after short periods of treatment ranging from 1
to 4 weeks, and even after single doses.
One suggested experimental medicine approach in Phase II
would be to define the target study population based on the
predicted mechanism of action. For example, given the implica-
tion of mu-opioid systems in binge eating [64], obese subjects with
prominent binge eating could represent a good target population
for opioid antagonists. 5-HT2C antagonism is a potential mechan-
ism implicated in weight gain induced by the antipsychotic clo-
zapine [65], and the 5-HT2C agonist lorcaserin might be a good
agent to trial in this population (the FDA requires agents for drug-
induced weight gain to be trialled in populations taking that
specific drug). The agent could then be tested in the sample in
a short study of 2–4 weeks using the appropriate biomarkers for the
predicted mechanism of action and potential adverse effects.*
*
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ates the recall of positive self-referent words (personality characteristics) [61].
ive self-referent words, reflected in greater number of errors in recognising
eferent words (here animal related words) (*P < 0.05).
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short durations, biomarker evidence of mechanistic efficacy and
safety would support decisions about whether to proceed with
further studies. It would be desirable to have biomarkers that could
predict future efficacy and even serve as surrogate endpoints but
this is more challenging. In the penultimate section we reflect on
the challenges and limitations of these biomarkers considering the
crucial matter of validation.
Challenges and limitations
There are several important caveats and challenges to consider
with these biomarkers. First, few of these have been used in studies
with antiobesity drugs and, in fact, this article has sought to
examine all of these. Second, most of these measures and their
analysis strategies have not been standardised. To improve their
specificity and permit comparisons across different studies and
compounds, standardisation is crucial. Third, given the variability
seen with these measures across studies, at present most can only
reliably be used to track changes from a pre-treatment baseline.
More importantly, there is the crucial matter of validation of
these biomarkers. There are two aspects to consider here. The first
is the validation of the measure in terms of its performance
characteristics and what it measures (i.e. does it reliably and
reproducibly measure what it is supposed to in different studies
and with different populations?) [26,66,67]. Essential to this, as
previously mentioned, is standardisation of the measure and also
the formulation of clear measurement endpoints. The biomarker
then needs to be consistently replicated in different samples. The
second aspect is more challenging and important; can the bio-
marker predict the clinical endpoint of efficacy and serve as a
surrogate endpoint? To determine this requires prospective larger
scale and longer term studies that can be used to model how the
biomarker and the process it captures predicts the clinical end-
point [26,66,67].
Surrogate endpoints will be a considerable body of work and it
can be argued that surrogate endpoints can have limited value in
antiobesity drug development given they are very unlikely to
support regulatory approval. One approach might be to apply
these biomarkers to the study of existing compounds in short
studies in healthy obese individuals [28,68,69]. A more pragmatic
approach might be to include some of these measures in the
current design of Phase I, II and even Phase III studies with new
compounds to build up an evidence base [11,37]. There is of course
the matter of cost: measures such as fMRI, particularly using the
necessary repeated measures, are expensive. However the cost of
running well-designed short proof-of-concept studies would be far
less than that of large Phase II and III trials.
The more pressing question is: what does a biomarker add to a
measure of weight change? It is a reasonable contention
that, under current regulations, there is no reason to advance apotential agent in the absence of a weight signal. Conversely, if an
agent does produce significant weight loss it can be argued that
biomarkers for proof-of-mechanism are not required and safety
concerns can arguably be reasonably determined in Phase II and
III. We would contend that weight loss without clear proof-of-
mechanism would be an unsatisfactory, although clearly not
untenable, position for a centrally acting agent. If there is
proof-of-mechanism with weight loss, biomarkers can facilitate
dose optimisation and the formulation of potential combination
treatments. What if there is proof-of-mechanism but no weight
loss? If dosing has been optimised, this might suggest that the
mechanism targeted is insufficient to affect weight loss alone but
could be potentially valuable as part of a combination treatment
with other pharmacological agents or with targeted behavioural
interventions, or as a potential agent for preventing weight
regain. Although the FDA and EMEA expect that a drug should
demonstrate efficacy for weight maintenance after weight loss,
given the current pharmacopoeia and regulatory framework it
could be some time before the idea of an agent purely for weight
maintenance gathers any traction, if at all. Finally, it is important
to note the value that these measures have in the characterisation
of the neural systems of appetite and reward in humans. This
latter point is key because it is only through a sophisticated
understanding of the pathways towards obesity that therapies
can be optimised and targeted effectively.
Concluding remarks
We have presented a case for the potential value of CNS biomar-
kers in antiobesity drug development, and identified some pro-
mising candidates that have been used thus far. However, the field
is still in its infancy and there remains a great deal of work to be
done before these biomarkers can be standardised and validated
and even more if they are to be used as potential surrogate end-
points. We accept that in the current regulatory requirement their
value might not be immediately apparent but they could become
invaluable as we work towards more sophisticated conceptualisa-
tions of obesity and antiobesity treatments.
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